T he tight regulation of therapeutic genes is of growing interest for gene therapy of cancer. If the combination of gene therapy with more conventional therapies of cancer is attempted, the control of therapeutic gene expression by exogenous factors such as drugs, irradiation, or heat shock is preferable. [1] [2] [3] This approach of combined therapeutic modalities requires vectors harboring inducible promoters to control the expression of the desired gene product. Numerous conditionally active promoters have been identified and tested, allowing their use as therapy-inducible vector systems. 4 The promoter of the human multidrug resistance gene (mdr1) harbors drug-responsive elements mediating the drug inducibility of the mdr1 gene expression. 5, 6 The mdr1 promoter has been characterized in reporter gene assays defining particular sequences; these sequences are drug-inducible by cytostatic drugs such as doxorubicin, etoposide, and vincristine, which are in routine clinical use in cancer chemotherapy. 7, 8 These observations made the mdr1 promoter an attractive candidate for use in a drug-inducible vector construct to express therapeutically relevant genes to augment the efficiency of chemotherapy. We have taken advantage of the human mdr1 promoter by using its drug inducibility for the expression regulation of the chemosensitizing cytokine tumor necrosis factor-␣ (TNF-␣).
Our therapeutic approach implies that the combination of gene therapy and chemotherapy can potentially result in a considerable improvement in anticancer efficacy. We have shown previously that cytokines such as TNF-␣ act as chemosensitizers for tumor cells by down-modulating the expression of genes associated with multidrug resistance (MDR). 9 -11 External treatment with TNF-␣ or transfer of the human TNF-␣ gene led to elevated drug accumulation in tumor cells accompanied by increased susceptibility of these tumor cells toward anticancer drugs.
functional in transduced tumors in vivo, and (b) whether the use of the vector system in cancer gene therapy in in vivo models is feasible for the strategy of combined gene therapy and chemotherapy of tumors.
MATERIALS AND METHODS

Cell line
The human mammary carcinoma cell line MCF-7 was maintained in Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, Md) supplemented with 10% fetal calf serum at 37°C and 5% CO 2
Transduction of tumor cells and establishment of tumors in nude mice
A total of 20 g of the pM3mdr-p-hTNF or pM3CMV-hTNF vector construct 13, 14 was introduced into 1 ϫ 10 6 MCF-7 cells by electroporation at 960 F, 300 V using the Gene Pulser (Bio-Rad, Richmond, Calif) apparatus. Transduced cell clones were selected in G418-containing medium for 14 days, and resistant colonies were then ring-cloned and expanded for further in vivo studies.
A total of 1 ϫ 10 7 transduced MCF-7 cells were transplanted along the right flank of 6-to 8-week-old female athymic mice. The animals were staged for 2-3 weeks to allow for the development of tumors with a size of ϳ6 ϫ 6 mm. Tumorbearing mice were randomized for the studies.
All mice bearing the MCF-7 breast carcinoma cells received a weekly estradiol supplementation of 0.5 mg/kg throughout the experiment.
Induction of TNF-␣ expression by cytostatic drugs
For evaluation of TNF-␣ induction in transduced tumors, animals with MCF-7 tumors were injected once with 8 mg/kg intravenous (i.v.) doxorubicin. The transduced tumor-bearing control animals received 0.9% sodium chloride solution at the same time in the same volume. The MCF-7 tumor-bearing animals were then sacrificed at days 1, 2, 3, 4, and 5 after the drug application to collect tumor and serum samples for TNF-␣ enzyme-linked immunosorbent assay (ELISA).
In a second set of experiments, MCF-7 tumor-bearing animals were injected once with 8 mg/kg i.v. doxorubicin or 1 mg/kg intraperitoneal vincristine. For a more individualized analysis of drug-induced TNF-␣ expression, tumor samples were taken by biopsy for TNF-␣ ELISA and reverse transcriptase-polymerase chain reaction (RT-PCR) at 4 hours, 1 day, and 2 days after drug application.
In all these studies, the tumor samples and biopsies were quick-frozen in liquid nitrogen before analysis.
TNF-␣ ELISA
For the TNF-␣ ELISA, tumor samples were homogenized in ice-cold tris(hydroxymethyl)aminomethane/ethylenediaminetetra acetic acid buffer (pH 8.0) containing the protease inhibitor aprotinin (10 mg/mL) and phenylmethylsulfonyl fluoride (100 g/mL). The homogenates were centrifuged at 14,000 rpm at 4°C for 10 minutes, 2 ϫ 100 L of the supernatants were subjected to the TNF-␣ ELISA (Cytoscreen ELISA; Biosource International, Camarillo, Calif) as duplicates, and the ELISA was performed according to the manufacturer's instructions. Absorbance was measured in a microplate reader at 450 nm (SLT Labinstruments, Crailsheim, Germany). The TNF-␣ values were calculated from the respective TNF-␣ standard curve using the EasySoftG200/Easy-Fit software (SLT Labinstruments) and normalized to the corresponding protein content of the tumor homogenates (determined by using the Coomassie Plus Protein Assay Reagent; Pierce, Rockford, Ill).
To determine the TNF-␣ in the serum of the animals, 50 L of the serum samples were subjected to the ultra-sensitive TNF-␣ ELISA (Biosource) and normalized to the corresponding serum protein content.
Analysis of TNF-␣ expression by RT-PCR
Total cellular RNA was isolated by using the LiCl/urea preparation protocol. 15 The RT-PCR was performed using the Gene Amp RNA PCR kit (Perkin Elmer, Norwalk, Conn). The RT reaction was carried out at 42°C for 15 minutes., followed by a denaturation step at 95°C for 5 minutes and a cooling step at 5°C for 5 minutes with 1 g of RNA and random hexamer primers supplied with the kit. For the PCR, TNF-␣-specific primers were used (amplifying a 702-bp product) and ␤-actin-specific primers were used (amplifying a 316-bp product). 16, 17 The PCR was performed at 95°C for 2 minutes and continued for 35 cycles of melting (95°C for 1 minute) and annealing-extending with thermostable Taq polymerase (60°C for 1 minute, followed by a final step at 72°C for 7 minutes). The PCR products were separated on a 1.5% agarose gel. Semiquantification was performed from video images by densitometry using the National Institutes of Health Image 1.44b11 software (obtained from Wayne Rasband, National Institute of Mental Health, Bethesda, Md). 
Determination of relative tumor volume
To evaluate the therapeutic efficacy of the combined action of cytostatic drugs and the drug-induced TNF-␣ expression, transduced MCF-7 tumor-bearing animals were treated twice within 7 days with 8 mg/kg i.v. doxorubicin. Tumor sizes were measured for the respective control and treated animals in two dimensions. Tumor volumes were calculated as (width 2 ϫ length)/2 and related to the corresponding sizes at the start of treatment (relative tumor volume).
Statistical analysis
Levels of statistical significance in the induction and in the tumor growth experiments were evaluated using the nonparametric Mann-Whitney rank sum test.
RESULTS
Drug-induced expression of TNF-␣ in pM3mdr-phTNF-transduced tumors
For the in vivo studies on drug induction of pM3mdr-phTNF-transduced tumors, MCF-7 cells were transfected ex vivo by electroporation. To ensure comparable basal expression levels of the cytokine, the cell clones were analyzed for TNF-␣ release before inoculation into the animals. Table 1 lists the levels of TNF-␣ secreted by the transduced MCF-7 clones, illustrating that the basal expression levels are not significantly different. Analyses of nontransduced parental MCF-7 cells revealed no expression of TNF-␣ at the mRNA (data not shown) or at the protein level.
In the first set of drug induction experiments, the established pM3mdr-p-hTNF-transduced MCF-7 tumor cell clones were inoculated into the animals. TNF-␣ expression was determined from the transduced tumors of animals that were treated once with 8 mg/kg i.v. for transduced MCF-7 tumors or from the respective transduced tumors from tumor-bearing control animals treated with saline. To determine vector-mediated induction of cytokine secretion after drug application, the animals were sacrificed at days 0, 1, 2, 3, 4, and 5. The tumor homogenates and serum samples were subjected to TNF-specific ELISA using an ELISA kit that does not detect murine TNF-␣ and that is specific for the cytokine expressed from the human cDNA. The TNF-␣ values, measured in duplicate, are depicted in Figure 2 . A total of 5 ng TNF-␣/mg tumor protein in the MCF-7 tumors (n ϭ 3) secreted at day 0 represents the basal level of mdr1 promoter-driven TNF-␣ expression, which remained unchanged in the saline-treated animals over the entire time period. Treatment with doxorubicin, however, leads to an increase of TNF-␣ secretion into the tumor, reflected by the up to 25-fold elevation in MCF-7 tumors (n ϭ 3) within 24 -48 hours after drug induction (Fig 2) . Analysis of the serum samples from both the drug-treated and control groups of MCF-7 tumor-bearing animals revealed no detectable TNF-␣ by the ultrasensitive ELISA, indicating that there is no measurable systemic release of the cytokine from either groups. Similar drug induction in vivo experiments in pM3mdr-p-hTNF-transduced HCT15 colon carcinoma tumors in nude mice supported these findings. A single application of 4 mg/kg i. v. doxorubicin led to an intratumoral increase in TNF-␣ expression within 24 -48 hours after the drug application (data not shown).
To gain more detailed information about the in vivo kinetics of drug induction, we performed a second set of experiments in which we tested two cytostatic drugs for induction of TNF-␣ expression, because previous in vitro experiments indicated that in addition to doxorubicin, vincristine can also induce mdr1 promoter-mediated gene expression. We treated pM3mdr-p-hTNF-transduced MCF-7 tumor-bearing mice once with 8 mg/kg i.v. doxorubicin (n ϭ 4) or 1 mg/kg intraperitoneal vincristine (n ϭ 4). We subsequently took biopsies from the tumors at 4, 24, and 48 hours after the drug application to individually follow the course of induced TNF-␣ expression at the mRNA level and at the protein level in these animals. Figure 3 shows the results of the TNFspecific ELISA of doxorubicin-treated (Fig 3A) or vincristine-treated (Fig 3B) animals and of the respective saline-treated control mice (Fig 3, A and B) . The drug treatment leads to a dramatic increase in TNF-␣ expression, with highest cytokine levels (70 -80 ng TNF-␣/mg tumor protein) 2 days after the drug application reflected by a maximum 6-fold increase in doxorubicintreated animals (P ϭ .00129) and a maximum 5-fold increase in vincristine-treated mice (P Ͻ .0001). The transduced tumor-bearing control animals (n ϭ 4) however, which received saline at the same time, showed no significant changes in TNF-␣ secretion. In these tumors, the cytokine was only expressed at basal levels ranging from 13 to 20 ng TNF-␣/mg tumor protein (Fig 3, A and  B ). These results demonstrate that a single administration of cytostatic drug is sufficient for effective drug induction of TNF-␣ expression, causing a transient accumulation of the cytokine within the tumor tissue.
The results obtained at the protein level with the TNF-␣-specific ELISA prompted us to confirm these data at the mRNA level to obtain further evidence that the increase in TNF-␣ secretion is indeed due to the mdr1 promoter-mediated, drug-induced expression. For the RT-PCR analysis, aliquots were taken from the same tumor biopsies that were subjected to the ELISA experiments. The isolated total cellular RNA was used for the TNF-and ␤-actin-specific RT-PCR, and the PCR products were semiquantitated from the video images. Figure  4 depicts representative RT-PCRs from animal 2 of the 
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doxorubicin-treated group (see Fig 3A) , animal 2 of the vincristine-treated group (see Fig 3B) , and animal 3 of the saline-treated control group (see Fig 3) . The RT-PCR reveals that in the drug-treated tumors, TNF-␣ mRNA expression is elevated at 4 hours after drug application compared with the saline control group ( Fig  4B) . Semiquantitative analysis of RNA expression from the video images indicates a 5.3-fold induction in doxorubicin-treated animals and a 3.5-fold induction in vincristine-treated animals 4 hours after drug treatment (Fig 4A) . Interestingly, TNF-␣ mRNA expression remains at elevated levels in both treatment groups up to 24 hours after drug administration and returns to the basal level 48 hours after the drug application (see Fig  4) . This indicates that the increase of TNF-␣ at the mRNA and protein level within the tumor tissue is a result of the time-dependent, drug-induced, mdr1 promoter-driven cytokine expression.
Influence of drug-induced TNF-␣ expression on growth in pM3mdr-p-hTNF-transduced tumors
To analyze the potential interaction and antitumoral activity between the drug-induced TNF-␣ expression and the inducing cytostatic drug, pM3mdr-p-hTNF (for drug-induced expression) or pCMV-hTNF (for constitutive expression), transduced and nontransduced MCF-7 tumor xenografts were grown to a size of 6 ϫ 6 mm before treatments began. As mentioned earlier, before inoculation of the transduced tumor cells into the animals, TNF-␣ amounts were determined to ensure that the basal expression levels of the cytokine were compa- Figure 2 . Induction of TNF-␣ expression by doxorubicin (F) or saline (E) in nude mice bearing pM3mdr-p-hTNF-transduced MCF-7 tumors. TNF-␣ expression was determined in tumor homogenates from animals sacrificed at indicated times after drug application using the human TNF-specific ELISA. Each point represents the mean TNF-␣ value of tumor homogenates from three different animals. In nontransduced MCF-7 tumors, no TNF-␣ was detectable in doxorubicin-or saline-treated animals (data not shown).
rable within the study (Table 1 ). The tumor-bearing animals were randomized and subsequently treated twice in a weekly interval with 8 mg/kg doxorubicin (see Fig 5) ; respective control animals were treated with saline at the same time. The effects of drug application and induced TNF-␣ expression were analyzed by determination of the tumor volumes at the indicated times. The parental nontransduced MCF-7 tumors showed no influence of either the saline or the doxorubicin treatment on growth behavior, which is consistent with the known relative insensitivity of this tumor model toward this cytostatic drug (Fig 5A) . However, in pM3mdr-phTNF-transduced tumors, treatment with doxorubicin caused a significant regression in tumor growth (Fig 5C) . The mean tumor volumes in these animals (n ϭ 6) were reduced to 31.7% of the respective saline-treated control group and to 23.4% of the corresponding nontransduced doxorubicin-treated parental MCF-7 tumors at 17 days after the second drug application (n ϭ 6) (see Fig 5A) . The TNF-␣ secretion itself, however, reduced the volume of the pM3mdr-p-hTNF-transduced tumors to 73.7% of the saline-treated parental tumors.
To gain better insight into whether the drug-induced TNF-␣ expression is advantageous compared with a constitutively active expression system, we analyzed the growth of pM3CMV-hTNF-transduced tumors in which TNF-␣ expression is driven by the human cytomegalo Representative TNF-specific RT-PCR of drug-induced TNF-␣ mRNA expression in pM3mdr-p-hTNF-transduced MCF-7 tumors by doxorubicin (DOX) or vincristine (VIN). Total cellular RNA was isolated from tumor biopsies and subjected to RT-PCR. The gels shown (B) were semiquantitated (A) (see Materials and Methods) and represent the TNF-␣-and ␤-actin-specific expression detected in RNAs from tumor biopsies of one individual animal at the indicated times treated with the respective cytostatic drug ‫,ء(‬ compare with the results of the TNF-␣ ELISAs shown for saline-treated animals (three animals), DOX-treated animal (two animals), and VIN-treated animals (two animals) in Figure 3, A and B) . Previous experiments have shown that expression of ␤-actin is not altered by drug application; therefore, expression of this gene was used for semiquantitative analysis of TNF-␣ expression. In nontransduced MCF-7 tumors, no TNF-␣-specific mRNA could be detected by the RT-PCR in doxorubicin-, vincristine-, or saline-treated animals (data not shown). , or pM3mdr-p-hTNF-transduced (C) tumors were treated twice with 8 mg/kg i.v. doxorubicin (f) or with saline (E) at the indicated days (marked by arrows). Relative tumor volumes were determined at indicated times and represent the mean values of six animals in each group. The asterisks indicate significant differences in tumor growth between the salinetreated control group and the doxorubicin-treated group; significance was determined by the Mann-Whitney rank sum test. A significance level of P Ͻ .05 was used for the definition of a significant therapeutic response.
virus (hCMV) promoter. Figure 5B depicts the growth of these tumors and indicates that the saline-treated group (n ϭ 6) is slightly delayed with regard to tumor growth compared with the parental MCF-7 tumor group (see Fig 5A) ; this may be attributed to the TNF-␣ secretion within these tumors. However, these tumors still reach 98.2% of the parental tumor size 12 days after the second saline treatment. Although treatment of the pM3CMV-hTNF-transduced tumors (n ϭ 6) with doxorubicin leads to a reduction in the mean tumor volume to 63.6% of the respective saline control group and 62.5% of the doxorubicin-treated parental tumors, this effect is not as dramatic as in pM3mdr-p-hTNF-transduced tumors. These data indicate that hCMV promoter-driven constitutive expression of the cytokine can exert improved antitumoral activity in conjunction with chemotherapy, however, with only a limited potential for synergy of gene therapy and chemotherapy.
DISCUSSION
In this study, we have demonstrated that the drugresponsive elements of the human mdr1 promoter can be employed to drive the expression of a therapeutically relevant gene within transduced tumors in vivo. We have used the human TNF-␣ gene for these experiments because of its antitumoral efficacy and its interactive antitumoral activity when combined with chemotherapy. 18 -20 Earlier investigations have shown that this cytokine possesses great chemosensitizing potential, rendering tumor cells more susceptible toward treatment with cytostatic drugs. 10, 21 Here we show that the novel vector system carrying the mdr1 promoter is inducible in vivo by cytostatic drugs such as doxorubicin or vincristine, which are in routine clinical use for cancer chemotherapy. Transduction of tumors with the vector pM3mdr-phTNF mediates gene activation targeted by chemotherapy, leading to the significant, transient increase of TNF-␣ expression and accumulation within tumors of animals treated with only a single dose of the cytostatic drug. The drug induction time-course we have observed in vivo is consistent with our previous in vitro findings, in which we also showed a dramatic increase in TNF-␣ expression 3-4 hours after drug application at the mRNA level and after 24 -120 hours at the protein level. 13 Interestingly, recent studies in sarcoma patients revealed a 3-to 13-fold induction of the mdr1 gene itself 50 minutes after drug application at the mRNA level, which supports our observation of a rapid and efficient mdr1 promoter response to drug treatments in the pM3mdr-p-hTNF transduced tumors. 22 The in vitro drug induction effects are only achieved by using MDRassociated drugs such as doxorubicin, vincristine, etoposide, or paclitaxel, whereas non-MDR drugs such as 5-fluorouracil did not induce the mdr1 promoter system. 13 Further extended investigations will reveal whether this also holds true for the in vivo situation.
Although we determined varying degrees of TNF-␣ protein induction levels in the two different experimental settings (TNF-␣ determination in whole tumor homogenates of sacrificed animals or in biopsies taken from living animals during observation time) after doxorubicin application in pM3mdr-p-hTNF-transduced MCF-7 tumors, these data support the feasibility of the vector system under in vivo conditions. This is even more important, because the pharmacology of drug application for expression induction in the intact animal is more complex compared with in vitro approaches, where the drug acts directly on the cells. It is important to note that a drug-induced elevation in TNF-␣ expression could be achieved at the mRNA and at protein level, although in these experiments the inducing drugs were applied only once. This indicates that a single drug induction is sufficient for the temporal accumulation of the cytokine within the transduced tumor, which can then be exploited for the combined treatment with chemotherapy at therapeutic doses of the relevant cytostatic drugs. The analyses of serum samples of the drug-induced transduced tumor-bearing animals showed no systemic release of the cytokine, indicating that the TNF-␣ secretion is restricted to the tumor; this observation is in agreement with findings described by others, who used intratumoral TNF-␣ gene transfer. 23 The concentration we determined in the transduced tumors was between 5 and 80 ng/mg protein, which is effective to exert antitumoral effects within the tumor but too low to cause an increase in the systemic TNF-␣ concentration. The cytokine has a half-life of only 3-5 minutes and therefore is cleared from the blood rapidly. 24 This is probably one important reason that we could not observe TNF-␣-related side effects in the animals, such as weight loss or sudden death.
It is known that both external application of TNF-␣ and transfer of the cytokine gene can influence tumor growth. 14, 25 However, external TNF-␣ treatment is often associated with systemic toxicity. 26 Furthermore, prolonged TNF-␣ treatment or constitutive cytokine expression after gene transfer may cause resistance of tumor cells toward the cytokine action.
27-29 Therefore, we compared the combined effects of drugs and TNF-␣ in tumors constitutively expressing TNF-␣ driven by the hCMV promoter with our conditionally active mdr1 promoter-harboring vector on tumor growth in vivo. The studies showed that the therapeutic advantage of the transient chemotherapy-controlled cytokine release at a higher level was reflected in the more pronounced growth inhibition in doxorubicin-treated pM3mdr-phTNF-transduced tumors. In pM3CMV-hTNF-transduced tumors, however, treatment with doxorubicin did not lead to significantly improved therapeutic efficacy, which may be attributed to the noninduced TNF-␣ level within this tumor tissue.
The major objective of this in vivo study was to evaluate the feasibility of using drug-inducible mdr1 promoter sequences to achieve a chemotherapy-regulatable temporal elevation in therapeutic gene expression; these sequences can augment the therapy with cytostatic drugs. The restricted expression of therapeutic genes such as TNF-␣ for the time required for chemotherapy of the tumor could confer a stringency of expression of the desired gene, minimizing potential side effects and the emergence of resistance phenomena.
